Rankings / Mood, Anxiety & Stress

Buspirone

Mood, Anxiety & Stress · 5-HT1A partial agonist

Tier B+

Reviewed by Read Off Label · Last reviewed · How we grade

prescription
7.1 / 10
Tier B+
Ev 6 Bn 5 Sf 9

Bottom line

Read Off Label grades Buspirone as B+ (7.1/10) based on moderate evidence, moderate benefit magnitude, and a low-risk safety profile.

RCT evidence supports buspirone as a non-addictive and minimally sedating anxiolytic for chronic GAD.

Studied, labeled, or reported-use context: 15-60 mg/day PO divided (2-3x/day) — Rx; not individualized guidance.

What the evidence says

RCT evidence supports buspirone as a non-addictive and minimally sedating anxiolytic for chronic GAD. Slow onset frustrates patients expecting benzodiazepine-speed effects. Often combined with SSRIs as augmentation.

Mechanism

Partial agonist at 5-HT1A receptors; weak D2 antagonist; no sedation, no tolerance, no addiction potential unlike benzodiazepines; used for chronic GAD

Studied, labeled, or reported dose & route

15-60 mg/day PO divided (2-3x/day)

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Buspirone's effects?
Read Off Label rates the evidence for Buspirone as Moderate and the benefit magnitude as moderate, producing an overall grade of B+ (7.1/10). RCT evidence supports buspirone as a non-addictive and minimally sedating anxiolytic for chronic GAD.
What safety findings are reported for Buspirone?
Buspirone has a low risk profile in the database. Low (dizziness, nausea, headache; minimal sedation; no dependence; effect takes 2-4 weeks) Legal status: Rx.
What doses or routes are reported for Buspirone?
15-60 mg/day PO divided (2-3x/day) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Buspirone work?
Partial agonist at 5-HT1A receptors; weak D2 antagonist; no sedation, no tolerance, no addiction potential unlike benzodiazepines; used for chronic GAD

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.